Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

CureVac N.V. CVAC NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • DE • USD

SharesGrow Score
73/100
5/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$5.00
+7.3%

CureVac N.V. (CVAC) is a Biotechnology company in the Healthcare sector, currently trading at $4.66. It has a SharesGrow Score of 73/100, indicating a above average investment profile with 5 out of 7 criteria passed.

Analyst consensus target is CVAC = $5 (+7.3% upside).

Financials: revenue is $535M, +280.2%/yr average growth. Net income is $162M, growing at +65.8%/yr. Net profit margin is 30.3% (strong). Gross margin is 80.2% (+211.5 pp trend).

Balance sheet: total debt is $39M against $697M equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 7.28 (strong liquidity). Debt-to-assets is 4.9%. Total assets: $803M.

Analyst outlook: 2 / 8 analysts rate CVAC as buy (25%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 70/100 (Pass), Future 40/100 (Partial), Income 100/100 (Pass).

$5.00
▲ 7.3% Upside
Average Price Target
The 12-month price target for CureVac N.V. is $5.00.

CVAC SharesGrow Score Overview

73/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 78/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 70/100
Gross margin is + market cap
FUTURE 40/100
Analyst outlook — as buy
INCOME 100/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CVAC

✓
VALUE Pass
78/100
CVAC trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $5, implying +7.3% from the current price $5. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
CVAC: +280.2%/yr revenue is, +65.8%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
CVAC: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✓
HEALTH Pass
100/100
Balance sheet CVAC: Debt-to-Equity (D/E) ratio 0.06 (conservative), Current ratio is 7.28 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
70/100
CVAC: Gross margin is 80.2% (+211.5 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
40/100
Analyst outlook: 2 / 8 analysts rate CVAC as buy (25%). Analyst consensus target is $5 (+7.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✓
INCOME Pass
100/100
CVAC: Net profit margin is 30.3%. strong (≥30%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.475-5.72
Volume728.78K
Avg Volume (30D)1.17M
Market Cap$1.05B
Beta (1Y)1.84
Share Statistics
EPS (TTM)0.72
Shares Outstanding$224.38M
IPO Date2020-08-14
Employees825
CEOAlexander Zehnder
Financial Highlights & Ratios
Revenue (TTM)$535.18M
Gross Profit$429.35M
EBITDA$209.69M
Net Income$162.19M
Operating Income$177.68M
Total Cash$485.37M
Total Debt$38.97M
Net Debt$-442.78M
Total Assets$802.83M
Price / Earnings (P/E)6.5
Price / Sales (P/S)1.96
Analyst Forecast
1Y Price Target$5.00
Target High$5.00
Target Low$5.00
Upside+7.3%
Rating ConsensusHold
Analysts Covering8
Buy 25% Hold 63% Sell 13%
Price Target Summary
Company Info
CountryDE
ExchangeNASDAQ Global Market
CurrencyUSD
ISINNL0015436031

Price Chart

Track all markets on TradingView
CVAC
CureVac N.V. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
2.48 52WK RANGE 5.72

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message